Valuation: Sprint Bioscience AB

Market Cap 386M 40.07M 35.01M 32.31M 29.78M 56.13M 3.86B 57.38M 152M 1.89B 150M 147M 6.51B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 386M 40.07M 35.01M 32.31M 29.78M 56.13M 3.86B 57.38M 152M 1.89B 150M 147M 6.51B EV / Sales 2026 *
4.55x
EV / Sales 2027 * 2.49x
Free-Float
64.78%
Yield 2026 *
-
Yield 2027 * -
1 day-1.61%
1 week-5.18%
Current month-11.59%
1 month-16.25%
3 months+7.96%
6 months+134.62%
Current year+148.98%
1 week 3.53
Extreme 3.53
3.9
1 month 3.53
Extreme 3.53
4.59
Current year 1.36
Extreme 1.355
4.59
1 year 0.5
Extreme 0.5
4.59
3 years 0.36
Extreme 0.36
4.59
5 years 0.36
Extreme 0.36
9.36
10 years 0.36
Extreme 0.36
41.9
Manager TitleAgeSince
Chief Executive Officer 42 01/10/2023
Chief Tech/Sci/R&D Officer 55 01/01/2009
Director of Finance/CFO 55 04/05/2026
Director TitleAgeSince
Chairman 70 01/01/2010
Director/Board Member 50 01/01/2019
Chairman 58 01/01/2021
Change 5-day change 1-year change 3-year change Capi.($)
-1.61%-5.18%+603.85%+603.85% 40.07M
-7.17%-4.39%+45.51%+79.00% 52.1B
+0.24%-1.54%+53.22%+71.85% 53.83B
+0.80%-6.31%+3.98%+423.29% 23.48B
-0.09%-0.01%-17.62%-14.67% 23.13B
-5.95%-2.58%+30.67%-9.58% 19.36B
-1.14%+0.03%+31.57%-30.42% 17.56B
-5.16%-7.00%+168.44%+306.37% 15.2B
-6.91%-5.83%+26.53%+636.97% 14.83B
+0.43%-1.03%+24.63%+191.40% 14.06B
Average -2.66%-2.88%+97.08%+225.80% 23.36B
Weighted average by Cap. -2.80%-2.36%+40.22%+144.18%

Financials

2026 *2027 *
Net sales 84.8M 8.8M 7.69M 7.09M 6.54M 12.33M 847M 12.6M 33.35M 415M 33.04M 32.32M 1.43B 155M 16.08M 14.05M 12.97M 11.95M 22.53M 1.55B 23.03M 60.97M 758M 60.39M 59.07M 2.61B
Net income - -
Net Debt - -
Logo Sprint Bioscience AB
Sprint Bioscience AB is a Sweden-based drug development company. It is engaged in the development of oncology therapeutics, focusing on cancer metabolism and liquid signaling. The Company's research is based on its fragment based drug discovery (FBDD) platform, which enables rapid indentifying of molecules with properties suitable for drug development. Its pipeline is divided in two research areas: cancer metabolism and autophagy, comprising products in the phases of establishing FBDD project and in the in vivo development. The Company’s strategy involves out-licensing or collaborating at an early stage of drug discovery in order to focus on current market needs.
Employees
30
Date Price Change Volume
17/07/26 SEK 3.660 -1.61% 138,947
16/07/26 SEK 3.720 +1.64% 193,962
15/07/26 SEK 3.660 -4.69% 245,551
14/07/26 SEK 3.840 +0.26% 67,770
13/07/26 SEK 3.830 -0.78% 258,970

Net sales - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SPRINT Stock